Title

Data on known anti-virals in combating CoVid-19

Authors

L. Akshayaa¹, Thangavelu Lakshmi^1*, Ezhilarasan Devaraj¹, Anitha Roy¹, S. Raghunandhakumar¹, P Sivaperumal¹, Sheba David², Kamal Dua^3,4 & Dinesh Kumar Chellappan⁵

Affiliation

¹Department of Pharmacology, Saveetha Dental College, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai-600077, TamilNadu; ²PAPRSB Institute of Health Sciences, Universiti Brunei Darussalam, Brunei; ³Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Ultimo, NSW, 2007, Australia; ⁴School of Biomedical Sciences and Pharmacy, University of Newcastle, Newcastle NSW 2308,Australia; ⁵Department of Life sciences, School of Pharmacy, International Medical University, Bukit Jalil, 57000, Kualalumpur, Malaysia

Email

Dr. Lakshmi Thangavelu – Email: lakshmi@saveetha.com; *Corresponding author

Article Type

Research Article

Date

Received October 9, 2020; Revised October 21, 2020; Accepted October 21, 2020; Published November 30, 2020

Design and development of effective anti-virals in combating CoVid-19 is a great challenge worldwide. Known drugs such as chloroquine, lopinavir, favipiravir and remdesivir are used in the management of CoVid - 19. It is known that Ivermectin and remdesivir both are effective against filoviruses, paramyxo viruses. Available data also shows that ivermectin and remedesivir repress the replication of SARS-CoV-2. Thus, we document the potential use of ivermectin and remdesivir in the management of CoVid -19.

Keywords

Molecular docking, HER-2 inhibitor, ZINC database, anticancer agent

Citation

Wali Sait et al. Bioinformation 16(11): 878-881 (2020)

Edited by

P Kangueane

ISSN

0973-2063

Publisher

Biomedical Informatics

License

This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License.